Tanshinone I inhibits tumor angiogenesis by reducing Stat3 phosphorylation at Tyr705 and hypoxia-induced HIF-1α accumulation in both endothelial and tumor cells

Oncotarget

Volumn 6, Issue 18, 2015, Pages 16031-16042

  Wang, Yan ^a,b   Li, Jia Xin ^a   Wang, Ying Qing ^a   Miao, Ze Hong ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b NANCHANG UNIVERSITY   (China)

Author keywords

Angiogenesis; HIF 1 ; Stat3; Tanshinone I; VEGF

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; STAT3 PROTEIN; TANSHINONE I; UBIQUITIN PROTEIN LIGASE; VASCULOTROPIN; ABIETANE DERIVATIVE; ANTINEOPLASTIC AGENT; MESSENGER RNA; SMALL INTERFERING RNA; TANSHINONE; TYROSINE;

ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CAPILLARY ENDOTHELIAL CELL; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENCY; ENZYME DEGRADATION; EX VIVO STUDY; GENE EXPRESSION REGULATION; HELA CELL LINE; HUMAN; HUMAN CELL; IC50; IN VIVO STUDY; LUNG CANCER CELL LINE; MCF 7 CELL LINE; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; ANIMAL; ANTAGONISTS AND INHIBITORS; AORTA; APOPTOSIS; CELL MOTION; CHICKEN; CHORIOALLANTOIS; CYTOLOGY; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; HYPOXIA; METABOLISM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; TUMOR CELL CULTURE; VASCULAR ENDOTHELIUM; VASCULARIZATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AORTA; APOPTOSIS; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; CHICKENS; CHORIOALLANTOIC MEMBRANE; DITERPENES, ABIETANE; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; HYPOXIA; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR; TUMOR CELLS, CULTURED; TYROSINE;

EID: 84937900578     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3648     Document Type: Article

References (34)

1. Jain RK. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell. 2014; 26:605-622.
2. Mullard A. Phase III setback for lead angiopoietin inhibitor. Nat Rev Drug Discov. 2014; 13:877-877.
3. Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhomme C, Richardson G, Rincon DG, et al. Antiangiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, doubleblind, placebo-controlled phase 3 trial. Lancet Oncol. 2014; 15:799-808.
4. Miao ZH, Feng JM, Ding J. Newly discovered angiogenesis inhibitors and their mechanisms of action. Acta Pharmacol Sin. 2012; 33:1103-1111.
5. Wang YQ, Miao ZH. Marine-derived angiogenesis inhibitors for cancer therapy. Mar Drugs. 2013; 11:903-933.
6. Yu B, Li MH, Wang W, Wang YQ, Jiang Y, Yang SP, Yue JM, Ding J, Miao ZH. Pseudolaric acid B-driven phosphorylation of c-Jun impairs its role in stabilizing HIF-1αlpha: a novel function-converter model. J Mol Med (Berl). 2012; 90:971-981.
7. Yu B, Miao ZH, Jiang Y, Li MH, Yang N, Li T, Ding J. c-Jun protects hypoxia-inducible factor-1alpha from degradation via its oxygen-dependent degradation domain in a nontranscriptional manner. Cancer Res. 2009; 69:7704-7712.
8. Zhou ZL, Luo ZG, Yu B, Jiang Y, Chen Y, Feng JM, Dai M, Tong LJ, Li Z, Li YC, Ding J, Miao ZH. Increased accumulation of hypoxia-inducible factor-1alpha with reduced transcriptional activity mediates the antitumor effect of triptolide. Mol Cancer. 2010; 9:268.
9. Zhou ZL, Yang YX, Ding J, Li YC, Miao ZH. Triptolide: structural modifications, structure-activity relationships, bioactivities, clinical development and mechanisms. Nat Prod Rep. 2012; 29:457-475.
10. Dai M, Miao ZH, Ren X, Tong LJ, Yang N, Li T, Lin LP, Shen YM, Ding J. MFTZ-1 reduces constitutive and inducible HIF-1αlpha accumulation and VEGF secretion independent of its topoisomerase II inhibition. J Cell Mol Med. 2010; 14:2281-2291.
11. Xu L, Feng JM, Li JX, Zhu JM, Song SS, Tong LJ, Chen Y, Yang XY, Shen YY, Lian FL, Li YP, Lin DH, Ding J, et al. Tanshinone-1 induces tumor cell killing, enhanced by inhibition of secondary activation of signaling networks. Cell Death Dis. 2013; 4:e905.
12. Dong Y, Morris-Natschke SL, Lee KH. Biosynthesis, total syntheses, and antitumor activity of tanshinones and their analogs as potential therapeutic agents. Nat Prod Rep. 2011; 28:529-542.
13. Wu WY, Wang YP. Pharmacological actions and therapeutic applications of Salvia miltiorrhiza depside salt and its active components. Acta Pharmacol Sin. 2012; 33:1119-1130.
14. Chen YJ, Chung TY, Chen WY, Chen CY, Lee MR, Jinn TR, Tc Tzen J. Detecting metabolites of different transition metal-lithospermate B complexes after intravenous injection in rats. Acta Pharmacol Sin. 2014; 35:937-944.
15. Nizamutdinova IT, Lee GW, Lee JS, Cho MK, Son KH, Jeon SJ, Kang SS, Kim YS, Lee JH, Seo HG, Chang KC, Kim HJ. Tanshinone I suppresses growth and invasion of human breast cancer cells, MDA-MB-231, through regulation of adhesion molecules. Carcinogenesis. 2008; 29:1885-1892.
16. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem. 1995; 270:1230-1237.
17. Yahata Y, Shirakata Y, Tokumaru S, Yamasaki K, Sayama K, Hanakawa Y, Detmar M, Hashimoto K. Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation. J Biol Chem. 2003; 278:40026-40031.
18. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature. 1996; 380:435-439.
19. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitinproteasome pathway. Proc Natl Acad Sci U S A. 1998; 95:7987-7992.
20. Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014; 14:736-746.
21. Atsumi T, Singh R, Sabharwal L, Bando H, Meng J, Arima Y, Yamada M, Harada M, Jiang JJ, Kamimura D, Ogura H, Hirano T, Murakami M. Inflammation amplifier, a new paradigm in cancer biology. Cancer Res. 2014; 74:8-14.
22. Middleton K, Jones J, Lwin Z, Coward JI. Interleukin-6: an angiogenic target in solid tumours. Crit Rev Oncol Hematol. 2014; 89:129-139.
23. Snyder M, Huang J, Huang XY, Zhang JJ. A signal transducer and activator of transcription 3. Nuclear Factor kappaB (Stat3.NFkappaB) complex is necessary for the expression of fascin in metastatic breast cancer cells in response to interleukin (IL)-6 and tumor necrosis factor (TNF)-alpha. J Biol Chem. 2014; 289:30082-30089.
24. Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S, Gritsko T, Turkson J, Kay H, Semenza GL, Cheng JQ, Jove R, Yu H. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene. 2005; 24:5552-5560.
25. Miklossy G, Hilliard TS, Turkson J. Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov. 2013; 12:611-629.
26. Li JX, Feng JM, Wang Y, Li XH, Chen XX, Su Y, Shen YY, Chen Y, Xiong B, Yang CH, Ding J, Miao ZH. The B-Raf(V600E) inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury. Cell Death Dis. 2014; 5:e1278.
27. Ren X, Dai M, Lin LP, Li PK, Ding J. Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent. Br J Pharmacol. 2009; 156:1228-1238.
28. Nicosia RF, Ottinetti A. Growth of microvessels in serumfree matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Invest. 1990; 63:115-122.
29. Belleri M, Ribatti D, Nicoli S, Cotelli F, Forti L, Vannini V, Stivala LA, Presta M. Antiangiogenic and vascular-targeting activity of the microtubule-destabilizing transresveratrol derivative 3, 5, 4'-trimethoxystilbene. Mol Pharmacol. 2005; 67:1451-1459.
30. Ribatti D, Vacca A, Roncali L, Dammacco F. The chick embryo chorioallantoic membrane as a model for in vivo research on anti-angiogenesis. Curr Pharm Biotechnol. 2000; 1:73-82.
31. Miao ZH, Ding J. Transcription factor c-Jun activation represses mdr-1 gene expression. Cancer Res. 2003; 63:4527-4532.
32. Jiang Y, Miao ZH, Xu L, Yu B, Gong JX, Tong LJ, Chen Y, Zhou ZL, Liu HC, Wang Y, Guo YW, Ding J. Drug transporter-independent liver cancer cell killing by a marine steroid methyl spongoate via apoptosis induction. J Biol Chem. 2011; 286:26461-26469.
33. Manzo SG, Zhou ZL, Wang YQ, Marinello J, He JX, Li YC, Ding J, Capranico G, Miao ZH. Natural product triptolide mediates cancer cell death by triggering CDK7-dependent degradation of RNA polymerase II. Cancer Res. 2012; 72:5363-5373.
34. Yi JM, Zhang XF, Huan XJ, Song SS, Wang W, Tian QT, Sun YM, Chen Y, Ding J, Wang YQ, Yang CH, Miao ZH. Dual Targeting of Microtubule and Topoisomerase II by α-Carboline Derivative YCH337 for Tumor Proliferation and Growth Inhibition. Oncotarget. 2015 (in press).